| Title |
The use of clonidine in elderly patients with delirium; pharmacokinetics and hemodynamic responses
|
|---|---|
| Published in |
BMC Pharmacology and Toxicology, June 2018
|
| DOI | 10.1186/s40360-018-0218-1 |
| Pubmed ID | |
| Authors |
Karen Roksund Hov, Bjørn Erik Neerland, Anders Mikal Andersen, Øystein Undseth, Vegard Bruun Wyller, Alasdair M. J. MacLullich, Eva Skovlund, Eirik Qvigstad, Torgeir Bruun Wyller |
| Abstract |
The Oslo Study of Clonidine in Elderly Patients with Delirium (LUCID) is an RCT investigating the effect of clonidine in medical patients > 65 years with delirium. To assess the dosage regimen and safety measures of this study protocol, we measured the plasma concentrations and hemodynamic effects of clonidine in the first 20 patients. Patients were randomised to clonidine (n = 10) or placebo (n = 10). The treatment group was given a loading dose (75μg every 3rd hour up to a maximum of 4 doses) to reach steady state, and further 75μg twice daily until delirium free for 2 days, discharge or a maximum of 7 days. Blood pressure (BP) and heart rate (HR) were measured just before every dose. If the systolic BP was < 100 mmHg or HR < 50 beats per minute the next dose was omitted. Plasma concentrations of clonidine were measured 3 h after each drug intake on day 1, just before intake (day 2 and at steady state day 4-6) and 3 h after intake at steady state (Cmax). Our estimated pre-specified plasma concentration target range was 0.3-0.7μg/L. 3 h after the first dose of 75μg clonidine, plasma concentration levels rose to median 0.35 (range 0.24-0.40)μg/L. Median trough concentration (C0) at day 2 was 0.70 (0.47-0.96)μg/L. At steady state, median C0 was 0.47 (0.36-0.76)μg/L, rising to Cmax 0.74 (0.56-0.95)μg/L 3 h post dose. A significant haemodynamic change from baseline was only found at a few time-points during the loading doses within the clonidine group. There was however extensive individual BP and HR variation in both the clonidine and placebo groups, and when comparing the change scores (delta values) between the clonidine and the placebo groups, there were no significant differences. The plasma concentration of clonidine was at the higher end of the estimated therapeutic range. Hemodynamic changes during clonidine treatment were as expected, with trends towards lower blood pressure and heart rate in patients treated with clonidine, but with dose adjustments based on SBP this protocol appears safe. ClinicalTrials.gov NCT01956604 , 09.25.2013. EudraCT Number: 2013-000815-26, 03.18.2013. Enrolment of first participant: 04.24.2014. |
X Demographics
The data shown below were collected from the profiles of 16 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 3 | 19% |
| Spain | 1 | 6% |
| Ireland | 1 | 6% |
| Belgium | 1 | 6% |
| Austria | 1 | 6% |
| Australia | 1 | 6% |
| Canada | 1 | 6% |
| Unknown | 7 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 9 | 56% |
| Scientists | 4 | 25% |
| Practitioners (doctors, other healthcare professionals) | 2 | 13% |
| Science communicators (journalists, bloggers, editors) | 1 | 6% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 59 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 8 | 14% |
| Student > Bachelor | 7 | 12% |
| Student > Ph. D. Student | 5 | 8% |
| Other | 4 | 7% |
| Researcher | 4 | 7% |
| Other | 10 | 17% |
| Unknown | 21 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 19 | 32% |
| Nursing and Health Professions | 5 | 8% |
| Neuroscience | 3 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 5% |
| Computer Science | 1 | 2% |
| Other | 9 | 15% |
| Unknown | 19 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2023.
All research outputs
#4,108,464
of 25,402,889 outputs
Outputs from BMC Pharmacology and Toxicology
#69
of 485 outputs
Outputs of similar age
#73,971
of 342,210 outputs
Outputs of similar age from BMC Pharmacology and Toxicology
#4
of 13 outputs
Altmetric has tracked 25,402,889 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 485 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 5.4. This one has done well, scoring higher than 85% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 342,210 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 13 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.